Next 10 |
home / stock / akro / akro articles
LOS ANGELES, June 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero...
SAN DIEGO, June 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutic...
LOS ANGELES, June 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class ...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero...
SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeut...
RANDOR, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a se...
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ:...
SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action law...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...